On Monday, H.C. Wainwright initiated coverage on Arcutis Biotherapeutics Inc . (NASDAQ:ARQT), issuing a Buy rating and setting a price target of $19.00. This aligns with the broader analyst consensus, as revealed by InvestingPro data, with price targets ranging from $12 to $29. According to the firm, Arcutis' Zoryve product line, which includes treatments for psoriasis and atopic dermatitis, is poised to become a leading topical agent in the inflammatory dermatology market.
The analyst noted the initial slow commercial launch of Zoryve cream but highlighted the subsequent release of Zoryve foam for seborrheic dermatitis as a significant growth catalyst. The impact is evident in the company's financial performance, with revenue growing an impressive 182.84% over the last twelve months and maintaining strong gross profit margins of 89.57%. The treatment addresses a market with up to 10 million affected individuals in the United States and few effective options. The success of the foam has also boosted the use of Zoryve cream for psoriasis patients.
Zoryve has outperformed competitors such as Vtama and is expected to effectively compete with topical JAK inhibitor Opzelura, particularly in pediatric care, due to its favorable tolerability profile. The lack of safety concerns associated with the JAK-inhibitor class further strengthens Zoryve's market position.
The analyst believes that while Arcutis' share price has already seen substantial growth, up 324% year-to-date compared to the biotech XBI's 9% increase, the market has yet to fully recognize the Zoryve franchise's potential.
According to InvestingPro analysis, the company appears undervalued despite its current market capitalization of $1.67 billion. With shares trading at less than three times the firm's 2027 sales estimate of $600 million, H.C. Wainwright anticipates that Zoryve could achieve $1 billion in sales across all indications by 2033.
The firm also suggests that as Zoryve demonstrates its commercial viability, it may become a target for strategic mergers and acquisitions. For deeper insights into Arcutis's valuation and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, along with 10 additional ProTips about the company's financial health and market position.
In other recent news, Arcutis Biotherapeutics has announced several key executive promotions, including Patrick Burnett to Executive Vice President, Chief Medical (TASE:PMCN) Officer, and L. Todd Edwards to Executive Vice President, Chief Commercial Officer.
These promotions are expected to bolster the growth and future prospects of the company and its ZORYVE® product line. In addition, Arcutis has reported a significant increase in sales for its ZORYVE portfolio, with a 452% year-over-year rise in net product revenues, totaling approximately $45 million.
The company also plans to expand ZORYVE's label, with approvals for additional indications expected by mid-2025. Furthermore, Arcutis has seen a 25% rise in total prescriptions for ZORYVE, with new prescriptions up by 23% quarter-over-quarter. In terms of financial health, the company aims to reach breakeven by 2026 without the need for further equity market funding.
Finally, Arcutis anticipates label expansion for ZORYVE to reach an additional 3.3 million patients and expects approvals for scalp and body psoriasis by mid-2025. Despite potential delays, the company is confident in securing Medicare Part D coverage for ZORYVE by 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.